Cryoport, Inc. (NASDAQ:CYRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Cryoport, Inc. (NASDAQ:CYRX) have received an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.50.

A number of analysts recently weighed in on CYRX shares. Roth Mkm reduced their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. UBS Group upped their target price on Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, October 18th.

Insider Transactions at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares in the company, valued at approximately $443,847.62. This represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the transaction, the chief executive officer now directly owns 731,897 shares in the company, valued at $4,764,649.47. The trade was a 6.39 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is currently owned by company insiders.

Institutional Trading of Cryoport

Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Cryoport by 3.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,522 shares of the company’s stock valued at $859,000 after purchasing an additional 1,438 shares in the last quarter. Comerica Bank raised its stake in Cryoport by 73.0% in the first quarter. Comerica Bank now owns 3,481 shares of the company’s stock worth $62,000 after buying an additional 1,469 shares in the last quarter. SG Americas Securities LLC bought a new position in Cryoport in the second quarter worth approximately $185,000. Assenagon Asset Management S.A. lifted its holdings in Cryoport by 52.9% during the second quarter. Assenagon Asset Management S.A. now owns 1,477,693 shares of the company’s stock worth $10,211,000 after buying an additional 511,064 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Cryoport by 13.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 169,155 shares of the company’s stock valued at $1,169,000 after acquiring an additional 19,803 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Trading Up 13.6 %

Shares of CYRX opened at $8.33 on Tuesday. The company’s fifty day simple moving average is $7.32 and its 200-day simple moving average is $8.16. The company has a market cap of $411.75 million, a P/E ratio of -2.46 and a beta of 1.62. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport has a twelve month low of $5.32 and a twelve month high of $20.10.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.